GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huaren Pharmaceutical Co Ltd (SZSE:300110) » Definitions » Return-on-Tangible-Asset

Huaren Pharmaceutical Co (SZSE:300110) Return-on-Tangible-Asset : 2.67% (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Huaren Pharmaceutical Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Huaren Pharmaceutical Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥64 Mil. Huaren Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥2,399 Mil. Therefore, Huaren Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 2.67%.

The historical rank and industry rank for Huaren Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300110' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -43.25   Med: 1.47   Max: 4.7
Current: -43.25

During the past 13 years, Huaren Pharmaceutical Co's highest Return-on-Tangible-Asset was 4.70%. The lowest was -43.25%. And the median was 1.47%.

SZSE:300110's Return-on-Tangible-Asset is ranked worse than
87.07% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs SZSE:300110: -43.25

Huaren Pharmaceutical Co Return-on-Tangible-Asset Historical Data

The historical data trend for Huaren Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huaren Pharmaceutical Co Return-on-Tangible-Asset Chart

Huaren Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.42 3.52 4.29 4.70 -42.75

Huaren Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.17 2.33 2.36 -191.25 2.67

Competitive Comparison of Huaren Pharmaceutical Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Huaren Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huaren Pharmaceutical Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huaren Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Huaren Pharmaceutical Co's Return-on-Tangible-Asset falls into.


;
;

Huaren Pharmaceutical Co Return-on-Tangible-Asset Calculation

Huaren Pharmaceutical Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-1368.479/( (4014.081+2387.881)/ 2 )
=-1368.479/3200.981
=-42.75 %

Huaren Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=64.112/( (2387.881+2409.731)/ 2 )
=64.112/2398.806
=2.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Huaren Pharmaceutical Co  (SZSE:300110) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Huaren Pharmaceutical Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Huaren Pharmaceutical Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Huaren Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 187 Zhuzhou Road, Qingdao, Shandong, CHN, 266100
Huaren Pharmaceutical Co Ltd is a China-based company engaged in the manufacture, and sale of non-polyvinyl chloride and Non-PVC large capacity preparations. Its categories of products include conventional infusion, therapy infusion, and nutrition infusion. The company distributes its products in domestic market, with Northeast China as its main market.
Executives
Yang Xiao Dong Director
Bo Guo Xiu Executives
Zhou Xi Jian Director
Mao Yu Wei Supervisors
Chu Xiao Jun Executives
Zhou Qiang Directors, executives
Ji Sheng Bin Executives
Xiao Wei Wen Executives
Shen Hong Ce Executives
Li Xiao Li Executives
Liu Qian Executives
Wang Wen Ping Executives
Liang Fu You Director
Liang Fu Dong Director
Gong Ling Secretary Dong

Huaren Pharmaceutical Co Headlines

No Headlines